Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.

Authors

E L. Simpson
J-P Lacour
L Spelman
R Galimberti
L F. Eichenfield
R Bissonnette
B A. King
J P. Thyssen
J I. Silverberg, George Washington University
T Bieber
K Kabashima
Y Tsunemi
A Costanzo
E Guttman-Yassky
L A. Beck
J M. Janes
A M. DeLozier
M Gamalo
D R. Brinker
T Cardillo
F P. Nunes
A S. Paller
A Wollenberg
K Reich

Document Type

Journal Article

Publication Date

1-5-2020

Journal

The British Journal of Dermatology

DOI

10.1111/bjd.18898

Comments

Online ahead of print

APA Citation

Simpson, E. L., Lacour, J., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., Kabashima, K., Tsunemi, Y., Costanzo, A., Guttman-Yassky, E., Beck, L. A., Janes, J. M., DeLozier, A. M., Gamalo, M., Brinker, D. R., Cardillo, T., Nunes, F. P., Paller, A. S., Wollenberg, A., & Reich, K. (2020). Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.. The British Journal of Dermatology, (). http://dx.doi.org/10.1111/bjd.18898

Peer Reviewed

1